gene

PLCG2

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about PLCG2: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

361Connections
3Hypotheses
5Analyses
50Outgoing
50Incoming
1Experiments
12Debates

Summary

A gene referenced in 1 knowledge graph relationship. Key connections: encodes PLCgamma2 (protein).

View on Wiki →

No AI portrait yet

🧬 Gene Info
Gene SymbolPLCG2
Full NamePhospholipase C Gamma 2
Chromosome16q23.3
Protein TypeEnzyme
Primary Expressionhematopoietic cells and microglia
Molecular Weight150 kDa
Amino Acids265 aa
PathwaysMAPK
UniProt IDP16885
NCBI Gene ID5336
Ensembl IDENSG00000197943
OMIM600220
GeneCardsPLCG2
Human Protein AtlasPLCG2
Associated DiseasesAD, AD risk, Aging, Als, Alzheimer, Alzheimer's disease
InteractionsActin, ALZHEIMER, ALZHEIMER DISEASE, ALZHEIMER'S DISEASE, AMYLOID, Amyloid Beta
SciDEX HypothesesCalibrated PLCG2 activation can reproduce the prot
PLCG2 Allosteric Modulation as a Precision Therape
Rare TREM2-TYROBP pathway variants complement stan
KG Connections361 knowledge graph edges
DatabasesGeneCardsHPASTRING
🔮 Predicted Structure: PLCG2 — AlphaFold P16885 Click to expand

AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

PLCG2 Gene

gene · 2789 words

PLCG2 Microglial Signaling Phagocytosis AD Causal Chain

mechanism · 1757 words

PLCG2 Protein

protein · 707 words

Pathway Diagram

graph TD
    PLCG2["PLCG2"]
    Cancer{"Cancer"}
    PLCG2 -->|"activates"| Cancer
    Carcinoma{"Carcinoma"}
    PLCG2 -->|"activates"| Carcinoma
    Ms{"Ms"}
    PLCG2 -->|"activates"| Ms
    PLCG2 -->|"inhibits"| Cancer
    PLCG2 -->|"inhibits"| Carcinoma
    Alzheimer{"Alzheimer"}
    PLCG2 -->|"associated with"| Alzheimer
    PLCG2 -->|"associated with"| Ms
    PLCG2 -->|"regulates"| Alzheimer
    Als{"Als"}
    PLCG2 -->|"associated with"| Als
    ABCB1["ABCB1"]
    PLCG2 -->|"contributes to"| ABCB1
    PARP1["PARP1"]
    PLCG2 -->|"contributes to"| PARP1
    DOT1L["DOT1L"]
    PLCG2 -->|"contributes to"| DOT1L
    DOT1L -->|"contributes to"| PLCG2
    ABCB1 -->|"contributes to"| PLCG2
    PARP1 -->|"contributes to"| PLCG2
    TREM2["TREM2"]
    TREM2 -->|"associated with"| PLCG2
    ABI3["ABI3"]
    ABI3 -->|"regulates"| PLCG2
    TREM2 -->|"regulates"| PLCG2
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"]
    ALZHEIMER_S_DISEASE -->|"regulates"| PLCG2
    AND["AND"]
    AND -->|"regulates"| PLCG2
    APP["APP"]
    APP -->|"associated with"| PLCG2
    ALZHEIMER_S_DISEASE -->|"associated with"| PLCG2
    NDUFAF7["NDUFAF7"]
    NDUFAF7 -->|"associated with"| PLCG2
    SHARPIN["SHARPIN"]
    SHARPIN -->|"associated with"| PLCG2
    style PLCG2 fill:#1a3a4a,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (237)

TargetRelationTypeStr
benchmark_ot_ad_answer_key:PLCG2data_indataset_row0.00
ds-f50762b67605provides_data_fordataset1.00
ds-db4a006ea647provides_data_fordataset1.00
ds-83b31ef18d49provides_data_fordataset1.00
TREM2-TYROBP signalingregulatespathway0.90

Incoming (124)

SourceRelationTypeStr
benchmark_ot_ad_answer_key:PLCG2data_indataset_row0.00
ds-f50762b67605data_indataset1.00
ds-83b31ef18d49data_indataset1.00
ds-db4a006ea647data_indataset1.00
h-d2937ed0targetshypothesis0.90

Targeting Hypotheses (3)

Hypotheses where this entity is a therapeutic target

HypothesisScoreDiseaseAnalysis
Calibrated PLCG2 activation can reproduce the protective rs7 0.650 alzheimers -
PLCG2 Allosteric Modulation as a Precision Therapeutic for T 0.532 neurodegeneration TREM2 agonism vs antagonism in DAM micro
Rare TREM2-TYROBP pathway variants complement standard PRS b 0.380 late-onset-alzheimers Polygenic Risk Score Analysis for Late-O

Mentioning Analyses (5)

Scientific analyses that reference this entity

TREM2 in Alzheimer's Disease: Mechanisms, Therapeutics, and Biomarkers

neurodegeneration | 2026-04-26 | 8 hypotheses Top: 0.861

Clinical Trial Landscaping for Alzheimer's Disease Therapeutics

neurodegeneration | 2026-04-16 | 1 hypotheses Top: 0.629

Can TREM2 receptor switching from agonism to antagonism be achieved safely witho

neurodegeneration | 2026-04-11 | 0 hypotheses

Which cell types show the most significant expression changes for neurodegenerat

neurodegeneration | 2026-04-03 | 6 hypotheses Top: 0.682

TREM2 agonism vs antagonism in DAM microglia

neurodegeneration | 2026-04-01 | 6 hypotheses Top: 0.886

Experiments (1)

Experimental studies targeting or related to this entity

ExperimentTypeDiseaseScoreFeasibilityModelStatusEst. Cost
E2F coordination of G2/M transcriptional program exploratory 0.750 0.00 endocycling mammalian cells proposed N/A

Related Papers (5)

Scientific publications cited in analyses involving this entity

Title & PMIDAuthorsJournalYearCitations
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] ["Chen Kai", "Li Fuyao", "Zhang Shuwen", Journal of neuroinflammation 2025 0
Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] ["Chen Kai", "Li Fuyao", "Zhang Shuwen", Journal of neuroinflammation 2025 0
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554] Marogianni C, Sokratous M, Dardiotis E, International journal of molec 2020 0
Neurodegeneration and Inflammation-An Interesting Interplay in Parkinson's Disea [PMID:33182554] Marogianni C, Sokratous M, Dardiotis E, International journal of molec 2020 0
Multiple Sclerosis Pathology. [PMID:29358320] Lassmann H Cold Spring Harbor perspective 2018 0

Debates (12)

Multi-agent debates referencing this entity

Extended debate: TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegenera

closed · Rounds: 6 · Score: 0.95 · 2026-04-27

Hypothesis debate: TREM2-Mediated Microglial Dysfunction Disrupts Perivascular T

closed · Rounds: 4 · Score: 0.50 · 2026-04-27

Hypothesis debate: PLCG2 Allosteric Modulation as a Precision Therapeutic for TR

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: PLCG2 Allosteric Modulation as a Precision Therapeutic for TR

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

Hypothesis debate: TREM2-Dependent Microglial Senescence Transition

closed · Rounds: 4 · Score: 0.64 · 2026-04-26

Hypothesis debate: TREM2-Dependent Astrocyte-Microglia Cross-talk in Neurodegene

closed · Rounds: 4 · Score: 0.50 · 2026-04-26

What are the key mechanistic, therapeutic, and diagnostic dimensions of TREM2 in

closed · Rounds: 4 · Score: 0.92 · 2026-04-26

What is the current clinical trial landscape for AD therapeutics, and which mech

closed · Rounds: 4 · Score: 0.70 · 2026-04-21

The stage-dependent strategy assumes sequential drug switching is feasible, but

closed · Rounds: 4 · Score: 0.50 · 2026-04-20

Is the amyloid concentration in AD clinical trials rational given lecanemab's ap

closed · Rounds: 4 · Score: 0.70 · 2026-04-16

Related Research

Hypotheses and analyses mentioning PLCG2 in their description or question text

No additional research found